Graham Parry - 21 Sep 2026 Form 4 Insider Report for Electra Therapeutics, Inc. (ETRA)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ETRA
Reported as of: 21 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Sep 2026, 18:17:32 UTC
Prior SEC filing: 18 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Jamie Kitano, Attorney-in-Fact

Key filing fact

Graham Parry filed Form 4 for Electra Therapeutics, Inc. (ETRA) on 21 Sep 2026.

Key facts

This page summarizes Graham Parry's Form 4 filing for Electra Therapeutics, Inc. (ETRA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Sep 2026, 18:17.

Change

Previous filing in this sequence was filed on 18 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002153366 Primary reporting owner

Parry Graham

Relationship: Chief Scientific Officer
Address: C/O ELECTRA THERAPEUTICS, INC., 230 E GRAND AVENUE, SUITE S-100, SOUTH SAN FRANCISCO
Signature: /s/ Jamie Kitano, Attorney-in-Fact
Signature date: 21 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETRA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +85,504
Change %
Price
Shares after: 85,504
Date: 21 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETRA transaction Derivative

Series A Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -85,504
Change %: -100%
Price
Shares after: 0
Date: 21 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 85,504
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

7,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026.

Footnote F2

Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.